Mast/stem cell growth factor receptor KIT is a receptor tyrosine kinase that plays a key role in mast cell differentiation, proliferation, survival and activation.
The cannabinoid CB1 receptor inverse agonist INV-202 (monlunabant) is in clinical studies at Inversago Pharma Inc. as a potentially first-in-class drug for metabolic disorders, including diabetic kidney disease and obesity.
Researchers from Tulane University identified NOX4, a ROS-generating enzyme, in epithelium near fibrotic foci in tissue biopsies of patients with IPF and linked its expression to epithelial cells senescence and persistence of aberrant transitional state leading to pulmonary fibrosis.
Idiopathic pulmonary fibrosis (IPF) is a disease in which several unique genes have shown expression in the lung tissue of patients with IPF. Previous findings had found the mRNA expression of band 4.1-like protein 3 (EPB41L3) to be 14-fold higher in lung fibroblasts from patients with IPF compared to control subjects.
South Korea’s Celltrion Inc. secured May 22 the European Commission’s go-ahead for Omlyclo (CT-P39) to be the first biosimilar to Genentech Inc./Novartis AG’s Xolair (omalizumab) in Europe for three of its major indications.
Interstitial lung fibrotic disease (ILD) is characterized by inflammation and fibrosis of lung tissue and is associated with poor prognosis. Gat Therapeutics SL has developed GTX-011, an orally available small molecule for treating fibrotic diseases.
α1-Antitrypsin deficiency is a hereditary disorder that affects the liver in children and adults, as well as the lungs in adults. The disease is mostly caused by the Z allele mutation in the SERPINA1 gene, where a glutamic acid amino acid is substituted by lysine (E342K) leading to protein misfolding and aggregation.
GSK plc’s interleukin-5 (IL-5) portfolio got boost as depemokimab, an ultra-long-acting biologic targeting IL-5, hit its endpoints in two phase III trials in severe asthma, setting up potential filings for the first therapy that could allow patients a six-month dosing schedule.
Shanghai Rulink Biopharma Co. Ltd. has synthesized integrin αvβ1, αvβ6 and/or αvβ8 antagonists reported to be useful for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis.
With positive phase IIa data for ENV-101 in idiopathic pulmonary fibrosis (IPF) in hand, showing some lung damage was reversed, Endeavor Biomedicines Inc. said it’s ready to begin further phase II studies in the indication.
RSS
